PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19738399-7 2009 A subtherapeutic dose of pioglitazone significantly suppresses the expression of TNF-alpha and IL-6 mRNA in WAT, but does not alter the serum glucose, insulin and WAT expression of adiponectin, adipocyte aP2 and LPL. Pioglitazone 25-37 lipoprotein lipase Mus musculus 212-215 27530729-8 2017 Pioglitazone dose-dependently decreased Tnf, Il6, Ccl2, Ptgs2, and Socs3 expression in WAT, in association with upregulation of Lpl, Ap2, Slc2a4, and Adipoq expression, indicating improvement in endotoxin-induced IR. Pioglitazone 0-12 lipoprotein lipase Mus musculus 128-131 19738399-8 2009 A therapeutic dose of pioglitazone improves insulin sensitivity, enhances LPL, aP2 and adiponectin expression, and also suppresses TNF-alpha and IL-6 expression. Pioglitazone 22-34 lipoprotein lipase Mus musculus 74-77 16894240-6 2006 After pioglitazone treatment, DGAT1 expression was increased by 33 +/- 10% (P < 0.05) and FAS expression increased by 63 +/- 8% (P < 0.05); however, LPL expression was not altered. Pioglitazone 6-18 lipoprotein lipase Mus musculus 155-158 14611672-6 2003 Moreover, up-regulation of the liver mRNA levels for lipoprotein lipase (LPL) was evident in the pioglitazone-treated animals. Pioglitazone 97-109 lipoprotein lipase Mus musculus 53-71 16606335-5 2006 Moreover, treatment with a peroxisome proliferator-activated receptor (PPAR) alpha agonist, bezafibrate, or a PPARgamma agonist, pioglitazone, suppressed both hyperlipidemia and intestinal polyp formation in the mice, with induction of LPL mRNA. Pioglitazone 129-141 lipoprotein lipase Mus musculus 236-239 14611672-6 2003 Moreover, up-regulation of the liver mRNA levels for lipoprotein lipase (LPL) was evident in the pioglitazone-treated animals. Pioglitazone 97-109 lipoprotein lipase Mus musculus 73-76 1538716-9 1992 Analysis of mRNA abundance for Glut-4, lipoprotein lipase, and glucose-6-phosphate dehydrogenase showed that pioglitazone enhanced the insulin induction of these mRNA species. Pioglitazone 109-121 lipoprotein lipase Mus musculus 39-57 12732191-0 2003 Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-gamma. Pioglitazone 91-103 lipoprotein lipase Mus musculus 0-18 12732191-4 2003 Pioglitazone increased LPL mRNA in WAT by 8-fold, which was substantially associated with a 4-fold increase of peroxisome proliferator activated receptor (PPAR)-gamma mRNA (r=0.97, p<0.0001), whereas pioglitazone did not affect LPL mRNA in SM. Pioglitazone 0-12 lipoprotein lipase Mus musculus 23-26 12732191-4 2003 Pioglitazone increased LPL mRNA in WAT by 8-fold, which was substantially associated with a 4-fold increase of peroxisome proliferator activated receptor (PPAR)-gamma mRNA (r=0.97, p<0.0001), whereas pioglitazone did not affect LPL mRNA in SM. Pioglitazone 0-12 lipoprotein lipase Mus musculus 231-234 12732191-5 2003 These results suggest that pioglitazone exclusively increases LPL production in WAT via stimulation of PPAR-gamma synthesis. Pioglitazone 27-39 lipoprotein lipase Mus musculus 62-65